Research Analysts’ Weekly Ratings Updates for Exelixis (EXEL)

Several brokerages have updated their recommendations and price targets on shares of Exelixis (NASDAQ: EXEL) in the last few weeks:

• 1/28/2025 – Exelixis had its price target raised by analysts at UBS Group AG from $30.00 to $34.00. They now have a “neutral” rating on the stock.
• 1/27/2025 – Exelixis was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $40.00 price target on the stock, up previously from $30.00.
• 1/27/2025 – Exelixis had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $29.00 price target on the stock.
• 1/27/2025 – Exelixis had its price target raised by analysts at Truist Financial Co. from $42.00 to $43.00. They now have a “buy” rating on the stock.
• 1/27/2025 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 1/24/2025 – Exelixis was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating. They now have a $33.00 price target on the stock, down previously from $41.00.
• 1/23/2025 – Exelixis had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $41.00 price target on the stock.
• 1/22/2025 – Exelixis had its “buy” rating reaffirmed by analysts at Guggenheim.
• 1/16/2025 – Exelixis had its price target raised by analysts at Oppenheimer Holdings Inc. from $38.00 to $41.00. They now have an “outperform” rating on the stock.
• 1/15/2025 – Exelixis had its price target raised by analysts at JMP Securities from $34.00 to $41.00. They now have a “market outperform” rating on the stock.
• 1/15/2025 – Exelixis had its price target raised by analysts at Truist Financial Co. from $38.00 to $42.00. They now have a “buy” rating on the stock.
• 1/13/2025 – Exelixis had its price target raised by analysts at Piper Sandler from $36.00 to $37.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Exelixis had its price target raised by analysts at HC Wainwright from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 1/7/2025 – Exelixis had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a “buy” rating on the stock.
• 12/23/2024 – Exelixis is now covered by analysts at Brookline Capital Management. They set a “buy” rating on the stock.
• 12/20/2024 – Exelixis was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $40.00 price target on the stock, up previously from $36.00.
• 12/17/2024 – Exelixis was downgraded by analysts at Bank of America Co. from a “buy” rating to a “neutral” rating. They now have a $39.00 price target on the stock, up previously from $35.00.

Exelixis Stock Performance

NASDAQ:EXEL opened at $32.80 on Monday. Exelixis, Inc. has a one year low of $20.01 and a one year high of $37.59. The firm has a market cap of $9.37 billion, a P/E ratio of 21.03, a P/E/G ratio of 0.72 and a beta of 0.53. The firm has a 50-day simple moving average of $34.68 and a 200-day simple moving average of $30.18.

Insider Activity

In other news, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the transaction, the executive vice president now owns 288,665 shares of the company’s stock, valued at $9,918,529.40. The trade was a 12.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 96,986 shares of Exelixis stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $17,463,075. The trade was a 16.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 208,574 shares of company stock worth $7,376,374. 2.85% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its position in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares during the last quarter. Covestor Ltd grew its position in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 341 shares during the last quarter. Principal Securities Inc. grew its position in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. V Square Quantitative Management LLC grew its position in Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 425 shares during the last quarter. Finally, Fifth Third Bancorp grew its position in Exelixis by 16.1% during the 4th quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 449 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.